High Throughput Screening (HTS) Market Research, 2033
The global high throughput screening (HTS) market was valued at $24.6 billion in 2023, and is projected to reach $62.8 billion by 2033, growing at a CAGR of 9.8% from 2024 to 2033. Surge in the prevalence of chronic diseases and rise in drug development is a major driver boosting high throughput screening (HTS) market.
Market Introduction and Definition
High throughput screening is the process of quickly analyzing hundreds to millions of samples for biological activity at the molecular, cellular, pathway, or model organism level using automated equipment. It is mostly employed to find physiologically significant molecules in drug discovery procedures. The pharmaceutical industry makes substantial use of high-throughput screening techniques, which combine robots and automation to rapidly test a huge number of molecules typically drugs for biological or biochemical activity. They expedite target analysis by enabling the rapid and economical screening of large-scale chemical libraries. HTS is a helpful method for evaluating, for example, pharmacological targets, agonists, and antagonists for receptors and enzymes, as well as pharmacological profiles of these compounds.
Key Takeaways
The high throughput screening (HTS) market size study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major high throughput screening industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
The high throughput screening (HTS) market report study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Key Market Dynamics
Rise in incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases has created a demand for new and effective therapeutic drugs, boosting the need for HTS in drug discovery. HTS plays a crucial role in identifying potential drug candidates quickly, thereby accelerating the drug development process, thereby driving high throughput screening (HTS) market size. HTS is integral to the development of personalized medicine, as it allows for the screening of large libraries of compounds to identify treatments tailored to individual genetic profiles. This approach enhances treatment efficacy and reduces adverse effects, driving the demand for HTS technologies.
The biopharmaceutical industry is expanding rapidly, with a growing focus on biologics and biosimilars. HTS is essential for the development of these complex molecules, as it enables the screening of large compound libraries to identify promising candidates, thereby driving high throughput screening (HTS) market growth. Furthermore, integration of advanced robotic systems and automation technologies has significantly enhanced the efficiency, speed, and accuracy of HTS processes. This reduces manual errors and increases throughput, making HTS more viable for large-scale applications.
Moreover, advances in microfluidics and the miniaturization of assays allow for the handling of smaller sample volumes. This not only reduces reagent costs but also increases the number of assays that can be performed simultaneously, improving overall efficiency. In addition, increasing investments by pharmaceutical and biotechnology companies in research and development drives the demand for HTS, thereby driving high throughput screening (HTS) market growth. These companies are focused on discovering new drugs and therapies to address unmet medical needs. Governments and public institutions are providing significant funding and support for scientific research, particularly in drug discovery and development, further boosting the high throughput screening market growth.
Moreover, collaborations between academic institutions, research organizations, and pharmaceutical companies foster innovation and accelerate the development and adoption of HTS technologies. These partnerships help in sharing knowledge, resources, and expertise, driving market growth. Thus, ongoing technological advancements, increasing investment in drug discovery, and rise in need for personalized medicine are driving the thereby driving high throughput screening (HTS) market forecast.
High Throughput Screening Market Patent Analysis, 2014-2024
Although the growth of high throughput screening market has been more rapid in recent years, the industry can draw on the patents filed by various companies. For instance, patents filed by the companies based in China dominated the same with 33.6% share, Patent Cooperation Treaty (PCT) , holds a share of about 15.9% and European Patent Office holds a share of about 9.9%.
Market Segmentation
The high throughput screening market is segmented into product & services, technology, application, end user, and region. On the basis of product & services, the market is categorized into instruments, consumables, and software & services. On the basis of technology, the market is categorized into cell based assays, lab-on-chip technology, and others. On the basis of application, the market is categorized into drug discovery, biochemical screening, and others. On the basis of end-user, the market is categorized into pharmaceutical & biotechnological companies, academic & research institutes, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional/Country Market Outlook
North America accounted for a major thereby driving high throughput screening (HTS) market share of the high throughput screening market owing to the presence of major players, well-established research infrastructure, recent technological advancements, and rise in chronic diseases.
Asia-Pacific high throughput screening (HTS) market share is estimated to grow with the highest CAGR during the forecast period, owing to the lucrative opportunities for the high throughput screening market key players, owing to a rise in the research & development activities. Another factor driving the growth of the market is the focus of major players on technological advancements in high throughput screening.
Industry Trends
- To improve data analysis, forecast medication responses, and more quickly find possible drug candidates, AI and ML are being more and more integrated into HTS platforms. With the use of these technologies, screening procedures can manage and evaluate the massive amounts of data produced, producing quicker and more accurate findings.
- The utilisation of microfluidic technology and the drive towards assay miniaturisation are becoming more popular. Throughput can be increased and reagent costs can be decreased by processing smaller sample volumes owing to these advances. HTS is more productive and economical when thousands of parallel experiments are carried out using microfluidic devices.
Recent Development in High Throughput Screening Industry
- In February 2024, SCIEX, announced the launch of the Echo MS+ system. The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results, through an expanded panel of robust high-throughput screening workflows.
- In March 2022, Promega Corporation announced the launch of bioluminescent assays that can quantitatively detect released cytokines from cell culture samples in 70 minutes. These luminescent assays are scalable for use in basic research or high-throughput screening for drug discovery and development.
Competitive Landscape
The major players operating in the high throughput screening market are Aurora Biomed Inc., Axxam S.p.A, Danaher Corporation, PerkinElmer, Inc., Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Biotek Instruments Inc., Merck Group KGaA, and Corning Incorporated.
Key Sources Referred
- National Center for Biotechnology Information
- World Health Organization (WHO)
- National Library of Medicine
- The United States Food and Drug Administration
- U.S. Department of Health & Human Services
- Centers for Disease Control and Prevention
- United States Environmental Protection Agency
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the high throughput screening (HTS) market analysis from 2024 to 2033 to identify the prevailing high throughput screening (HTS) market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the high throughput screening (HTS) market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global high throughput screening (HTS) market trends, key players, market segments, application areas, and market growth strategies.
High Throughput Screening (HTS) Market Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 62.8 Billion |
 Growth Rate | CAGR of 9.8% |
 Forecast period | 2024 - 2033 |
 Report Pages | 280 |
 By Product & Services |
|
 By Technology |
|
 By Application |
|
 By Region |
|
 Key Market Players | PerkinElmer, Inc., Bio-Rad Laboratories Inc, Agilent Technologies, Inc., Biotek Instruments Inc., Thermo Fisher Scientific Inc., Axxam S.p.A, Merck Group KGaA, Aurora Biomed Inc, Danaher Corporation, Corning Incorporated |
Rise in incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders are the upcoming trends ofhigh throughput screening (HTS) market in the globe.
Drug discovery is one of the is the lucrative application of high throughput screening (HTS) market.
North America is the largest regional market for high throughput screening (HTS).
The global high throughput screening (HTS) market was valued at $24.6 billion in 2023, and is projected to reach $62.8 billion by 2033, growing at a CAGR of 9.8% from 2024 to 2033.
The major players operating in the high throughput screening market are Aurora Biomed Inc., Axxam S.p.A, Danaher Corporation, PerkinElmer, Inc., Bio-Rad Laboratories Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, Biotek Instruments Inc., Merck Group KGaA, and Corning Incorporated.
Loading Table Of Content...
